IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Digestive System Neoplasms

Interventions

COMBINATION_PRODUCT

Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab

radiotherapy + rmhTNF-NC + tislelizumab

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT07196540 - IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx | Biotech Hunter | Biotech Hunter